Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Taking 1mg finasteride tablets for 6 months can lower good cholesterol (HDL) and raise triglycerides in men with hair loss.

This commentary discusses the practice of prescribing and dividing Proscar tablets for cost-effective finasteride use and reports no new clinical findings.

This study developed a rapid and sensitive HPLC method for measuring finasteride in bulk and tablet forms, showing high precision and accuracy compared to the official method.

New, cheaper method measures finasteride in tablets accurately and quickly.

This article narrates a case where a patient with androgenetic alopecia faced high out-of-pocket costs for finasteride 1 mg and sought to reduce expenses by requesting a prescription for 5 mg tablets typically used for BPH, which are covered by insurance.

This case report hypothesizes that finasteride 1mg daily may influence melasma development in men by affecting estrogen and progesterone levels in the skin.

Method accurately measures finasteride in tablets using finasteride-BSA interaction.

This study found that finasteride test and reference tablets are bioequivalent in healthy male volunteers, with no significant differences in their pharmacokinetic parameters.

This study found that in patients with androgenetic hair loss, taking 1 mg of finasteride daily significantly raised triglyceride levels and decreased HDL levels after 3 and 6 months.

In this case report, the authors describe a 38-year-old male who developed painless hematuria and hematospermia, likely of prostatic origin, associated with finasteride treatment for androgenic alopecia.

This study validated a new RP-HPLC method for accurately determining doxazosin mesylate and finasteride in bulk powders and capsule formulations.

This article reviews the mechanism, use, and alternatives for finasteride in dermatology and provides no new clinical results.

This study describes a new colorimetric method for accurately and precisely measuring finasteride in tablets, with results comparable to the standard HPLC method.

In this study, the release rate of Finasteride from Eudragit matrix tablets was found to be significantly influenced by the drug/Eudragit ratio and polymer viscosity, with formulation F9 being the most effective.

This study found that the orally disintegrating tablet and standard tablet formulations of finasteride met bioequivalence criteria in fasting healthy adult male Han Chinese volunteers, although there was a significant difference in time to maximum concentration.

This article reviews multiple entries on the Androlog blog regarding finasteride use, concluding that a 1-mg dose does not adversely affect spermatogenesis or pose a risk during conception or pregnancy.

This study demonstrated that using finasteride impurity as a non-isotopically labeled internal standard in paper spray ionization–mass spectrometry can effectively and efficiently measure finasteride tablet dissolution, achieving results comparable to high-performance liquid chromatography.

This study developed a rapid and sensitive method for determining finasteride concentrations in pharmaceuticals, with results comparable to those from the standard HPLC method.

This study found that finasteride 1 mg was effective in improving androgenetic alopecia over 10 years in men, particularly those older than 30, with some reporting beneficial results even after 5 years.

This study observed that long-term use of finasteride in Japanese men with androgenetic alopecia was associated with progressive hair regrowth in 87.1% of participants without significant safety concerns.

Finasteride can cause one-sided breast enlargement, which disappears after stopping the drug.

In this study, finasteride 1 mg demonstrated sustained efficacy over 10 years for men with androgenetic alopecia, especially in those over 30 or with higher AGA grades, with minimal side effects reported.

This study found no significant associations between the polymorphisms of SRD5A1 and SRD5A2 genes and androgenetic alopecia, clinical types of baldness, or response to finasteride in Koreans.

The authors concluded that a finasteride every other month regimen had similar maintenance effects to a daily regimen in men with androgenetic alopecia.

This article reviews existing treatments for male-pattern hair loss, noting that while they can slow progression, they generally achieve only partial hair regrowth.

This research describes CG2001's promising safety profile and reduced systemic exposure as an alternative to finasteride, supporting its further development for androgenic alopecia treatment in future trials.

This study found that in male Wistar rats, finasteride administration reduced neural cellular activity markers and 5-alpha reductase type 2 expression in brain tissue, with some recovery occurring after drug withdrawal, unlike persistent 5-alpha reductase type 2 suppression.

This meta-analysis reported that finasteride 1 mg/day significantly increased hair count in male androgenetic alopecia compared to placebo, but highlighted persistent sexual side effects and associated depression risk.

This study concluded that daily treatment with 1 mg finasteride did not affect spermatogenesis or semen production in young men and had small, reversible effects on prostate volume and serum PSA.

In this study, finasteride 1 mg/day for 12 months did not improve hair growth or slow hair thinning in postmenopausal women with androgenetic alopecia compared to placebo.